Answers are grounded in this paper and cite their sources.
Retrospective analysis reports on sensory neuropathies in patients, suggesting further study on autoantibodies.
Background: Neuronopathies or ganglionopathies constitute a group of relatively rare sensory neuropathies, resulting from involvement of the dorsal root ganglion. This condition was first described in 1948 and has a distinct clinical presentation from other sensory neuropathies, mostly affecting deep sensitivity with a non-length-dependent pattern. It typically manifests with sensory ataxia and areflexia. Objective: To characterize clinically, epidemiologically and neurophisiologically the cases of ganglionopathies observed in our service. Methods: A retrospective study was conducted by reviewing the medical records of ganglionopathy cases treated between 2018 and 2024. Results: 10 diagnosed cases were identified with ganglionopathy during the study period. The average age of the patients was 59.8 years, with a predominance among women (60%) and symptom onset within 5 years in 70%. Disease presentation was chronic in 90% of cases, initially affecting lower limbs in 70% of cases, although with disease progression, 90% of patients eventually presented involvement of both upper and lower limbs. Half of the patients reported paresthesia as the initial symptom, while others reported ataxia (30%) and pain (20%). Only 30% of patients had pure deep sensitivity impairment, even though all of them predominantly exhibited this type of sensory deficit. Two patients presented with associated cerebellar involvement, 90% of cases presented with hyporeflexia or areflexia, mainly in the lower limbs. Etiologically, half of the cases remained idiopathic, while 2 cases were associated with Sjogren’s syndrome, 2 cases with Paraneoplastic syndrome and 1 case with vitamin B12 deficiency. The majority of cases (90%) were treated with immunosuppressive therapy or vitamin b12 supplementation, but only 5 patients reported symptom improvement after treatment, mostly ataxia improvement. Among the 5 cases that showed symptom improvement, 4 patients (80%) received pulse therapy with methylprednisolone. Regarding electroneuromyography, there was a predominance of asymmetric and severe axonal impairment of nerves, with 60% of cases characterized as sensory axonal neuropathy and 20% as sensory-motor axonal neuropathy. Conclusion: Our aim is to contribute to the characterization of this relatively rare and understudied condition, encouraging further research in this area, especially its etiology with the identification of autoantibodies potentially associated with this condition, as well as uncertainties regarding appropriate therapeutic choices.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: